OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BB BIOTECH N Stock

Certificat

DE000SV3HX12

Market Closed - Bid/Ask 02:31:22 2024-05-28 EDT After market 14:00:05
1.75 EUR +3.55% Intraday chart for OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BB BIOTECH N 1.77 +1.14%
Current month+1.81%
1 month-4.52%
Date Price Change
24-05-28 1.75 +3.55%
24-05-27 1.69 +0.60%
24-05-24 1.68 +2.44%
24-05-23 1.64 -5.20%
24-05-22 1.73 +7.45%

Delayed Quote Börse Stuttgart

Last update May 28, 2024 at 02:31 am

More quotes

Static data

Product typeCertificat Turbo Stop Loss
Buy / SellPUT
Underlying BB BIOTECH AG
IssuerLogo Issuer Société Générale Société Générale
WKN SV3HX1
ISINDE000SV3HX12
Date issued 2023-03-28
Strike 57.76 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 1.24
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.63
Lowest since issue 1.11
Spread 0.06
Spread %3.33%

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.6 CHF
Average target price
47.7 CHF
Spread / Average Target
+17.49%
Consensus